When to use a reduced NOAC dose

Prof. Danilo Toni discusses findings from the RE-AFFIRM study for patients with prior stroke treated with Rivaroxaban vs. Warfarin in clinical routine and puts the data from the randomized controlled trial ROCKET AF into perspective

© Bayer AG, 2020 | Approval number PP-XAR-ALL-1767-1

Overview of the PIONEER AF-PCI trial assessing the safety and efficacy of rivaroxaban compared with a VKA in patients with AF undergoing PCI

© Bayer AG, 2020 | Approval number PP-XAR-ALL-0042-1

The study assessed the safety and efficacy of rivaroxaban compared with warfarin in patients with NVAF for the prevention of stroke. These results were consistent with real-world evidence seen in prospective non-interventional studies

© Bayer AG, 2020 | Approval number PP-XAR-ALL-0097-2

Patients receiving anticoagulation with a NOAC should receive a reduced dose in certain clinical situations

© Bayer AG, 2020 | Approval number PP-XAR-ALL-1742-1

The XANTUS programme evaluated the safety and efficacy of rivaroxaban in real-world patients with NVAF across the globe

© Bayer AG, 2020 | Approval number PP-XAR-ALL-0639-1

Professor Craig Coleman outlines the considerations when treating frail patients with AF

© Bayer AG, 2020 | Approval number PP-XAR-ALL-0710-1